Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

209 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Ravulizumab in Atypical Hemolytic Uremic Syndrome: An Analysis of 2-Year Efficacy and Safety Outcomes in 2 Phase 3 Trials.
Dixon BP, Kavanagh D, Aris ADM, Adams B, Kang HG, Wang E, Garlo K, Ogawa M, Amancha P, Chakravarty S, Heyne N, Kim SH, Cataland S, Yoon SS, Miyakawa Y, Luque Y, Muff-Luett M, Tanaka K, Greenbaum LA. Dixon BP, et al. Among authors: cataland s. Kidney Med. 2024 Jun 14;6(8):100855. doi: 10.1016/j.xkme.2024.100855. eCollection 2024 Aug. Kidney Med. 2024. PMID: 39105067 Free PMC article.
An expert discussion on the atypical hemolytic uremic syndrome nomenclature-identifying a road map to precision: a report of a National Kidney Foundation Working Group.
Nester CM, Feldman DL, Burwick R, Cataland S, Chaturvedi S, Cook HT, Cuker A, Dixon BP, Fakhouri F, Hingorani SR, Java A, van de Kar NCAJ, Kavanagh D, Leung N, Licht C, Noris M, O'Shaughnessy MM, Parikh SV, Peyandi F, Remuzzi G, Smith RJH, Sperati CJ, Waldman M, Walker P, Vivarelli M. Nester CM, et al. Among authors: cataland s. Kidney Int. 2024 Sep;106(3):326-336. doi: 10.1016/j.kint.2024.05.021. Kidney Int. 2024. PMID: 39174192 Free article.
Relapse-free survival is progressively shortened in a subset of Black patients with immune-mediated TTP treated in the rituximab era.
Fatola A, Evans MD, Brown J, Davis E, Johnson A, Antun AG, Farland AM, Woods R, Metjian A, Park YA, de Ridder G, Gibson B, Kasthuri RS, Liles DK, Eubanks S, Akwaa F, Clover T, Kreuziger LB, Sadler JE, Sridharan M, Go RS, McCrae KR, Upreti HV, Lim MY, Kocher NK, Gangaraju R, Zheng XL, Raval JS, Masias C, Cataland SR, Mazepa M, Chaturvedi S. Fatola A, et al. Among authors: cataland sr. Blood Adv. 2025 Jan 28;9(2):417-424. doi: 10.1182/bloodadvances.2024013313. Blood Adv. 2025. PMID: 39626301
Caplacizumab improves clinical outcomes and is well tolerated across clinically relevant subgroups of patients with immune-mediated thrombotic thrombocytopenic purpura.
Pavenski K, Scully M, Coppo P, Cataland S, Knöbl P, Peyvandi F, Kremer Hovinga JA, de la Rubia J, Khan U, Marques AP, Gunawardena S. Pavenski K, et al. Among authors: cataland s. Res Pract Thromb Haemost. 2024 Jul 15;8(5):102512. doi: 10.1016/j.rpth.2024.102512. eCollection 2024 Jul. Res Pract Thromb Haemost. 2024. PMID: 39221451 Free PMC article.
Recombinant ADAMTS13 in Congenital Thrombotic Thrombocytopenic Purpura.
Scully M, Antun A, Cataland SR, Coppo P, Dossier C, Biebuyck N, Hassenpflug WA, Kentouche K, Knöbl P, Kremer Hovinga JA, López-Fernández MF, Matsumoto M, Ortel TL, Windyga J, Bhattacharya I, Cronin M, Li H, Mellgård B, Patel M, Patwari P, Xiao S, Zhang P, Wang LT; cTTP Phase 3 Study Investigators. Scully M, et al. Among authors: cataland sr. N Engl J Med. 2024 May 2;390(17):1584-1596. doi: 10.1056/NEJMoa2314793. N Engl J Med. 2024. PMID: 38692292 Clinical Trial.
209 results